These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23217530)

  • 21. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
    Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
    J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Alzheimer drugs: life-threatening adverse effects.
    Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
    Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
    Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
    Aguglia E; Onor ML; Saina M; Maso E
    Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
    McCain KR; Sawyer TS; Spiller HA
    Ann Pharmacother; 2007 Oct; 41(10):1632-7. PubMed ID: 17848422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
    Herrmann N; Binder C; Dalziel W; Smyth S; Camacho F
    Drugs Aging; 2009; 26(5):403-7. PubMed ID: 19552492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticholinesterase duration in the Australian veteran population.
    Gadzhanova S; Roughead L; Mackson J
    Aust N Z J Psychiatry; 2010 May; 44(5):469-74. PubMed ID: 20397790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complete atrioventricular block during galantamine therapy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2006 Apr; 150(17):989-90; author reply 990. PubMed ID: 17225744
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
    Fisher A; Carney G; Bassett K; Dormuth CR
    Drugs Aging; 2017 Mar; 34(3):221-231. PubMed ID: 28138912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients.
    Thacker EL; Schneeweiss S
    Drug Saf; 2006; 29(11):1077-85. PubMed ID: 17061913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
    Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
    CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
    Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease.
    Isik AT; Bozoglu E; Naharci MI; Kilic S
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):454-9. PubMed ID: 21335298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
    Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
    Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A population-based study of cholinesterase inhibitor use for dementia.
    Herrmann N; Gill SS; Bell CM; Anderson GM; Bronskill SE; Shulman KI; Fischer HD; Sykora K; Shi HS; Rochon PA
    J Am Geriatr Soc; 2007 Oct; 55(10):1517-23. PubMed ID: 17697100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.